Designed multiple ligands may exert improved efficacy with lower incidence of side effects.
A series of 6-aryl-indenoisoquinolone derivatives were described as dual ERα and VEGFR-2 inhibitors.
Compound 21c turned out to be a promising dual targeting candidate for breast cancer.